Sugi Predict

Sugi Predict / Compounds / SCHEMBL24207010

SCHEMBL24207010

SCHEMBL24207010

Cc1cc(N)ccc1N1CCC(CO)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.59
▸ GAA P10253 6/20 0.59
▸ ALDH1A1 P00352 6/20 0.59
▸ MEN1 O00255 4/20 0.59
▸ KMT2A Q03164 4/20 0.59
▸ THRB P10828 3/20 0.59
▸ NR4A1 P22736 2/20 0.59
▸ PTK2B Q14289 1/20 0.59
▸ RAD52 P43351 2/20 0.56
▸ GFER P55789 2/20 0.56
▸ HTT P42858 2/20 0.48
▸ KDM4E B2RXH2 4/20 0.44
▸ ALOX15 P16050 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ POLB P06746 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ YWHAG P61981 1/20 0.38
▸ HTR3E A5X5Y0 1/20 0.37
▸ HTR3B O95264 1/20 0.37
▸ HTR3A P46098 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22403756 0.88 ALDH1A1 (0.63) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL19998345 0.85 MAPT (0.59) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL24206879 0.83 MAP2K7 (0.46) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL188448 0.83 MAPT (0.65) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL17264116 0.82 MAPT (0.69) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL20231853 0.82 MAPT (0.54) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL29890862 0.82 MAPT (0.54) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL24865510 0.81 ALDH1A1 (0.71) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL29990141 0.81 ALDH1A1 (0.71) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL3440300 0.80 MAPT (0.54) MAPTGAAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2023-08-24 — — US disclosed
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2023-08-24 — — US disclosed
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2023-08-24 — — US disclosed
CN-116323580-A Conjugated degradation (EGFR) of EGFR inhibitors to E3 ligase ligands and methods of use 百济神州有限公司 2023-06-23 — — CN disclosed
WO-2023083194-A1 WEE1 PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF 杭州格博生物医药有限公司 2023-05-19 — — WO disclosed
WO-2022012622-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE, LTD. (KY) 2022-01-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE EGFR, CBL, ERBB2 MAPT 3181/4885GAA 1842/4885ALDH1A1 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.